Application of antibody induction therapy in liver transplantation

doi:10.3877/cma.j.issn.1674-3903.2018.02.008

Abstract

Abstract:

The application of biological protein preparation, antibody, as an immunosuppressive therapy during the early stage of organ transplantation, can significantly reduce the risk of early acute rejection after organ transplantation without increasing postoperative infection. In the meantime, it can also delay or reduce the use of CNI. These advantages mean this therapy is beneficial for protecting renal function, graft function recovery and the long-term survival of recipients. By summarizing the characteristics and mechanisms of the common antibody immunization inducers, this paper tries to analyze the clinical benefits and risks of different antibody induction therapy in liver transplantation, hoping to provide reference for rational use of antibody induction therapy in liver transplantation.

Key words: Induction therapy, Antibody, Liver transplantation, Acute rejection

Kuifen Ma, Xuejuan Zhu, Yin Wu, Quanjin Chen, Xiaoxin Xu, Guiping Guo, Yao Lu. Application of antibody induction therapy in liver transplantation[J]. Chinese Journal of Transplantation(Electronic Edition), 2018, 12(02): 80-85.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhyzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3903.2018.02.008

https://zhyzzz.cma-cmc.com.cn/EN/Y2018/V12/I02/80

References 40

1	Germani G,Rodriguez-Castro K,Russo FP, et al. Markers of acute rejection and graft acceptance in liver transplantation[J]. World J Gastroenterol, 2015，21(4): 1061-1068.
2	Kotsch K,Ulrich F,Reutzel-Selke A, et al. Methylprednisolone therapy in deceased donors reduces inflammation in the donor liver and improves outcome after liver transplantation: a prospective randomized controlled trial[J]. Ann Surg, 2008，248(6): 1042-1050.
3	Benítez CE,Puig-Pey I,López M, et al. ATG-Fresenius treatment and low-dose tacrolimus: results of a randomized controlled trial in liver transplantation[J]. Am J Transplant, 2010，10(10): 2296-2304.
4	Flechner SM,Kobashigawa J,Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity[J]. Clin Transplant, 2008，22(1): 1-15.
5	Sgourakis G,Dedemadi G. Corticosteroid-free immunosuppression in liver transplantation: an evidence-based review[J]. World J Gastroenterol, 2014，20(31): 10703-10714.
6	Magliocca JF,Knechtle SJ. The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation[J]. Transpl Int, 2006，19(9): 705-714.
7	Turner AP,Knechtle SJ. Induction immunosuppression in liver transplantation: a review[J]. Transpl Int, 2013，26(7): 673-683.
8	Boillot O,Seket B,Dumortier J, et al. Thymoglobulin induction in liver transplant recipients with a tacrolimus, mycophenolate mofetil, and steroid immunosuppressive regimen: a five-year randomized prospective study[J]. Liver Transpl, 2009，15(11): 1426-1434.
9	耿兴超,周洋,林志，等. 抗CD3单克隆抗体对食蟹猴免疫功能及相关基因表达的影响[J]. 中国药学杂志，2016，51(1): 20-27.
10	Kauffman HM,Cherikh WS,McBride MA, et al. Deceased donors with a past history of malignancy: an organ procurement and transplantation network/united network for organ sharing update[J]. Transplantation, 2007，84(2): 272-274.
11	尤平洪,卢一平. 一种新型的IL-2R受体阻滞剂——抗CD25单克隆抗体[J]. 华西医学，2007，22(3): 659-660.
12	Hanaway MJ,Woodle ES,Mulgaonkar S, et al. Alemtuzumab induction in renal transplantation[J]. N Engl J Med, 2011，364(20): 1909-1919.
13	Macklin PS,Morris PJ,Knight SR. A systematic review of the use of rituximab as induction therapy in renal transplantation[J]. Transplant Rev (Orlando), 2015，29(2): 103-108.
14	van den Hoogen MW,Kamburova EG,Baas MC, et al. Rituximab as induction therapy after renal transplantation: a randomized, double-blind, placebo-controlled study of efficacy and safety[J]. Am J Transplant, 2015，15(2): 407-416.
15	Galante NZ. Induction treatment in renal transplantation[J]. J Bras Nefrol, 2015，37(2): 156-157.
16	Wiseman AC. Induction therapy in renal transplantation: Why? What Agent? What Dose? We may never know[J]. Clin J Am Soc Nephrol, 2015，10(6): 923-925.
17	倪之嘉,丁国善,于勇，等. 巴利昔单抗在预防肝移植术后排斥反应中的应用[J]. 第二军医大学学报，2007，28(6): 678-680.
18	刘颖,朱志军. 达利珠单抗免疫诱导治疗在肝移植后的应用[J]. 中国组织工程研究，2013，17(31): 5601-5606.
19	Xiao M,Xu X,Zhu H, et al. Efficacy and safety of basiliximab in liver transplantation for patients with hepatitis B virus-related diseases: a single centre study[J]. Int J Clin Pract Suppl, 2015，69(183): 35-42.
20	Onali S,Mansell A,Aspite S, et al. Reduced calcineurin inhibitor exposure early after liver transplantation protects against renal dysfunction independently of the use of basiliximab induction therapy[J]. J Hepatol, 2015，62 (S2): S323-S324.
21	Hagopian J,Horwedel T,Bowman L, et al. Renal function following basiliximab induction in liver transplant recipients[J]. Am J Transplant, 2015，15 (S3)．
22	Werth J,Ally W,Maluf D, et al. Basiliximab induction with delayed tacrolimus initiation up to 14 days post liver transplantation maintains excellent clinical outcomes while preserving renal function[J]. Am J Transplant, 2015，15 (S3)．
23	Hibi T,Shinoda M,Itano O, et al. Steroid minimization immunosuppression protocol using basiliximab in adult living donor liver transplantation for hepatitis C virus-related cirrhosis[J]. Hepatol Res, 2015，45(12): 1178-1184.
24	Goralczyk AD,Hauke N,Bari N, et al. Interleukin 2 receptor antagonists for liver transplant recipients: a systematic review and meta-analysis of controlled studies[J]. Hepatology, 2011，54(2): 541-554.
25	Crins ND,Röver C,Goralczyk AD, et al. Interleukin-2 receptor antagonists for pediatric liver transplant recipients: a systematic review and meta-analysis of controlled studies [J]. Pediatr Transplant, 2014，18(8): 839-850.
26	Wang XF,Li JD,Peng Y, et al. Interleukin-2 receptor antagonists in liver transplantation: a meta-analysis of randomized trials[J]. Transplant Proc, 2010，42(10): 4567-4572.
27	Hall D,Puri S,Mabry S, et al. Forty-seven consecutive simultaneous liver-kidney transplants with steroid free immunosuppression after rabbit antithymocyte globulin induction[J]. Am J Transplant, 2015，15 (S3)．
28	Yoo MC,Vanatta JM,Modanlou KA, et al. Steroid-free liver transplantation using rabbit antithymocyte globulin induction in 500 consecutive patients[J]. Transplantation, 2015，99(6): 1231-1235.
29	Penninga L,Wettergren A,Wilson CH, et al. Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients[J]. Cochrane Database Syst Rev, 2014，(6): CD010253.
30	Penninga L,Wettergren A,Wilson CH, et al. Antibody induction versus corticosteroid induction for liver transplant recipients[J]. Cochrane Database Syst Rev, 2014，(5): CD010252.
31	Montenovo MI,Jalikis FG,Li M, et al. Superior patient and graft survival in adult liver transplantation with rabbit antithymocyte globulin induction: Experience with 595 patients[J]. Exp Clin Transplant, 2017，15(4): 425-431.
32	Uemura T,Schaefer E,Hollenbeak CS, et al. Outcome of induction immunosuppression for liver transplantation comparing anti-thymocyte globulin, daclizumab, and corticosteroid[J]. Transpl Int, 2011，24(7): 640-650.
33	Lu B,Park KT,Balise RR, et al. The use of daclizumab or antithymocyte globulin (ATG) for induction in pediatric liver transplantation does not increase the risk of epstein-barr virus (EBV) viremia post transplantation but does shorten the time interval to the development[J]. Hepatology, 2011，54 (S1): 706A-707A.
34	Hotta R,Ohira M,Matsuura T, et al. CD52-negative NK cells are abundant in the liver and less susceptible to alemtuzumab treatment[J]. PloS One, 2016，11 (8): e0161618.
35	Uryuhara K. Successful protocol with rituximab in adult living donor liver transplantation across ABO barrier[J]. Transpl Int, 2015，28 (S4): 201.
36	Lee J,Lee JG,Song SH, et al. Results of ABO incompatible liver transplantation using a simplified protocol at a single institution[J]. Transpl Int, 2015，28 (S4): 5.
37	Song GW,Lee SG,Hwang S, et al. ABO-incompatible adult living donor liver transplantation under the desensitization protocol with rituximab[J]. Am J Transplant, 2016，16(1): 157-170.
38	Egawa H,Umeshita K,Uemoto S. The best regimen with rituximab for ABO-incompatible living donor liver transplantation[J]. Am J Transplant, 2015，15 (S3)．
39	Lee S,Kim SH,Park SJ, et al. ABO incompatible living donor liver transplantation using rituximab without plasma exchange[J]. HPB (Oxford), 2015，17 (S2): 59.
40	Okada N,Snada Y,Hirata Y, et al. The impact of rituximab in ABO-incompatible pediatric living donor liver transplantation: the experience of a single center[J]. Pediatr Transplant, 2015，19(3): 279-286.

[1]	Xining Wu, Yunshu Ouyang, Yixiu Zhang, Hua Meng, Zhonghui Xu, Peipei Zhang, Ke Lyu. Application of fetal echocardiography in prenatal management of fetuses with positive maternal anti-SSA/Ro-SSB/La antibodies [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(10): 1056-1060.
[2]	Kunhe Li, Mengjia Kou, Liting Kuang. Risk factors and prediction model of reintubation after liver transplantation [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(05): 366-371.
[3]	Branch of Organ Transplant of Chinese Medical Association, Branch of Organ Transplant Physicians of Chinese Medical Doctor Association, Shanghai Pharmaceutical Profession Association. Expert Consensus on the Use of Mycophenolic Acid in Chinese Liver and Kidney Transplant Recipients (2023 edition) [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(05): 257-272.
[4]	Wenqing Lu, Xinyi Chen, Xuefei Ren. Investigation on the quality of life after liver transplantation in children with genetic metabolic diseases [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(05): 287-292.
[5]	Tieyan Fan, Jun Li, Hong Chen. Diagnosis and treatment experience of new onset viral hepatitis E after liver transplantation [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(05): 293-296.
[6]	Shuo Chen, Feng Chen, Fei Cheng, Jie Xiang. Pancreas infarction after liver transplantation for glycogen storage disease type Ⅰ complicated with pancreatitis: a case report [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(05): 300-302.
[7]	Penghao Tang, Wu Zhang. Progress in mechanism research about intestinal microecology with perioperative complications of liver transplantation [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(05): 303-307.
[8]	Lina Zhu, Zizhen Yang, Di Zhang, Yong Zhang, Jinzhen Cai, Jianhong Wang. The application value of contrast-enhanced ultrasound in the diagnosis of hepatic artery complications after liver transplantation [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(04): 240-245.
[9]	Committee of Health Management for Organ Transplant Recipient, China Organ Transplantation Development Foundation, Branch of Organ Transplant Physicians of Chinese Medical Doctor Association, Branch of Organ Transplant of Chinese Medical Association, National Center for Healthcare Quality Management in Liver Transplant. Chinese expert consensus on clinical application of inhibitors of mammalian target of rapamycin in liver transplant recipients (2023 edition) [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(04): 193-204.
[10]	Qing Yan, Ying Liu, Feiwen Deng, Huanwei Chen. Effect of microvascular invasion on survival and prognosis of liver transplantation recipients with liver cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 624-629.
[11]	Mei Liao, Hongjun Zhang, Jieyang Jin, Yan Lyu, Jie Ren. Diagnostic value of bedside contrast-enhanced ultrasound for early hepatic artery thrombosis after liver transplantation [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 630-634.
[12]	Binglin Li, Shaocheng Lyu, Fei Pan, Tao Jiang, Hua Fan, Jiantao Kou, Qiang He, Ren Lang. Correlation analysis between pathogenic bacteria of donor liver perfusion fluid and early infection after liver transplantation [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 656-660.
[13]	Lei Lyu, Xiao Feng, Kaiming He, Kaining Zeng, Qing Yang, Haijin Lyu, Huimin Yi, Shuhong Yi, Yang Yang, Binsheng Fu. Value of revised King's score in evaluation of live transplantation timing for children with acute liver failure due to Wilson's disease and literature review [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 661-668.
[14]	Menglong Wang. Significance of biological characteristics in liver transplantation for HCC [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(05): 490-494.
[15]	Yemei Dai, Xiaole Su, Lihua Wang. Research progress on target antigens of membranous nephropathy [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2023, 12(05): 282-286.

Please choose a citation manager

Content to export